253 related articles for article (PubMed ID: 22938516)
1. An evidence-based meta-analysis of vascular endothelial growth factor inhibition in pediatric retinal diseases: part 1. Retinopathy of prematurity.
Mititelu M; Chaudhary KM; Lieberman RM
J Pediatr Ophthalmol Strabismus; 2012; 49(6):332-40. PubMed ID: 22938516
[TBL] [Abstract][Full Text] [Related]
2. Bilateral effect of unilateral bevacizumab injection in retinopathy of prematurity.
Karaca C; Oner AO; Mirza E; Polat OA; Sahiner M
JAMA Ophthalmol; 2013 Aug; 131(8):1099-101. PubMed ID: 23744183
[No Abstract] [Full Text] [Related]
3. An updated study of the use of bevacizumab in the treatment of patients with prethreshold retinopathy of prematurity in taiwan.
Wu WC; Kuo HK; Yeh PT; Yang CM; Lai CC; Chen SN
Am J Ophthalmol; 2013 Jan; 155(1):150-158.e1. PubMed ID: 22967867
[TBL] [Abstract][Full Text] [Related]
4. Vitrectomy after intravitreal bevacizumab (Avastin) for retinal detachment in retinopathy of prematurity.
Kychenthal A; Dorta P
Retina; 2010 Apr; 30(4 Suppl):S32-6. PubMed ID: 20224474
[TBL] [Abstract][Full Text] [Related]
5. Retinal detachment despite aggressive management of aggressive posterior retinopathy of prematurity.
Suk KK; Berrocal AM; Murray TG; Rich R; Major JC; Hess D; Johnson RA
J Pediatr Ophthalmol Strabismus; 2010 Dec; 47 Online():e1-4. PubMed ID: 21175113
[TBL] [Abstract][Full Text] [Related]
6. Apelin in epiretinal fibrovascular membranes of patients with retinopathy of prematurity and the changes after intravitreal bevacizumab.
Zhang Y; Jiang YR; Lu Q; Yin H; Tao Y
Retina; 2013 Mar; 33(3):613-20. PubMed ID: 23296045
[TBL] [Abstract][Full Text] [Related]
7. Current and future trends in treatment of severe retinopathy of prematurity.
Wallace DK; Wu KY
Clin Perinatol; 2013 Jun; 40(2):297-310. PubMed ID: 23719311
[TBL] [Abstract][Full Text] [Related]
8. A rare association of intravitreal bevacizumab injection with double ridge formation in retinopathy of prematurity.
Yaz Y; Erol N; Gursoy H; Basmak H; Bilgec MD
J Pediatr Ophthalmol Strabismus; 2014 Oct; 51 Online():e66-8. PubMed ID: 25333243
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal bevacizumab for retinopathy of prematurity: refractive error results.
Harder BC; Schlichtenbrede FC; von Baltz S; Jendritza W; Jendritza B; Jonas JB
Am J Ophthalmol; 2013 Jun; 155(6):1119-1124.e1. PubMed ID: 23490192
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal anti-VEGF therapy as a treatment for retinopathy of prematurity: what we know after 7 years.
Klufas MA; Chan RV
J Pediatr Ophthalmol Strabismus; 2015; 52(2):77-84. PubMed ID: 25798707
[TBL] [Abstract][Full Text] [Related]
11. Time to consider a new treatment protocol for aggressive posterior retinopathy of prematurity?
Spandau U; Tomic Z; Ewald U; Larsson E; Akerblom H; Holmström G
Acta Ophthalmol; 2013 Mar; 91(2):170-5. PubMed ID: 22268644
[TBL] [Abstract][Full Text] [Related]
12. Combined intravitreal bevacizumab injection and zone I sparing laser photocoagulation in patients with zone I retinopathy of prematurity.
Kim J; Kim SJ; Chang YS; Park WS
Retina; 2014 Jan; 34(1):77-82. PubMed ID: 23807184
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal bevacizumab following laser therapy for severe retinopathy of prematurity.
Erol N; Gürsoy H; Sahin A; Basmak H
J Pediatr Ophthalmol Strabismus; 2010 Aug; 47 Online():e1-4. PubMed ID: 21158371
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: comparison between Ranibizumab and Bevacizumab.
Chen SN; Lian I; Hwang YC; Chen YH; Chang YC; Lee KH; Chuang CC; Wu WC
Retina; 2015 Apr; 35(4):667-74. PubMed ID: 25462435
[TBL] [Abstract][Full Text] [Related]
15. Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in taiwan.
Wu WC; Yeh PT; Chen SN; Yang CM; Lai CC; Kuo HK
Ophthalmology; 2011 Jan; 118(1):176-83. PubMed ID: 20673589
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal bevacizumab as supplemental treatment or monotherapy for severe retinopathy of prematurity.
Axer-Siegel R; Snir M; Ron Y; Friling R; Sirota L; Weinberger D
Retina; 2011; 31(7):1239-47. PubMed ID: 21555969
[TBL] [Abstract][Full Text] [Related]
17. Combine intravitreal bevacizumab injection with laser treatment for aggressive posterior retinopathy of prematurity (AP-ROP).
Wutthiworawong B; Thitiratsanont U; Saovaprut C; Subhangkasen I; Geyuraphun B; Ampornprut A; Phumongkutchai J; Tephusdinnaayuthaya S
J Med Assoc Thai; 2011 Aug; 94 Suppl 3():S15-21. PubMed ID: 22043749
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II.
Mintz-Hittner HA; Kuffel RR
Retina; 2008 Jun; 28(6):831-8. PubMed ID: 18536599
[TBL] [Abstract][Full Text] [Related]
19. Reactivation of retinopathy of prematurity after ranibizumab treatment.
Wong RK; Hubschman S; Tsui I
Retina; 2015 Apr; 35(4):675-80. PubMed ID: 25768252
[TBL] [Abstract][Full Text] [Related]
20. Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity.
Wu WC; Lien R; Liao PJ; Wang NK; Chen YP; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC
JAMA Ophthalmol; 2015 Apr; 133(4):391-7. PubMed ID: 25569026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
